Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laszlo Endrenyi

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Clinical Therapeutics|August 19, 2011
The need for additional metrics to assess therapeutic equivalence of some multiphasic modified-release productsPeter M Kondra, Laszlo Endrenyi, Laszlo Tothfalusi
Statistics in Medicine|August 21, 2012
Comments on the FDA draft guidance on biosimilar productsShein-Chung Chow, Laszlo Endrenyi, Peter A Lachenbruch
Statistics in Medicine|August 23, 2012
On the interchangeability of biologic drug productsLaszlo Endrenyi, Chiann Chang, Shein-Chung Chow, et al.
Statistics in Medicine|August 31, 2012
Scientific considerations for assessing biosimilar productsShein-Chung Chow, Jun Wang, Laszlo Endrenyi, et al.
Journal of Biopharmaceutical Statistics|August 8, 2014
Scientific factors and current issues in biosimilar studiesShein-Chung Chow, Laszlo Endrenyi, Peter A Lachenbruch, et al.
Statistics in Medicine|August 31, 2012
Impact of variability on the choice of biosimilarity limits in assessing follow-on biologicsNan Zhang, Jun Yang, Shein-Chung Chow, et al.
Pharmacogenetics and Genomics|December 14, 2007
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazineEleni Aklillu, Werner Kalow, Laszlo Endrenyi, et al.
Omics : a Journal of Integrative Biology|October 31, 2017
Stop the Spam! Conference Ethics and Decoding the Subtext in Post-Truth Science. What Would Denis Diderot Say?Vural Özdemir, Collet Dandara, Nezih Hekim, et al.
Clinical Therapeutics|April 20, 2012
Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteriaMegan J Shram, Anne Marie Quinn, Nancy Chen, et al.
Journal of Clinical Psychopharmacology|March 2, 2005
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategyLawrence J Albers, Vural Ozdemir, Stephen R Marder, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Clinical Therapeutics|August 19, 2011
The need for additional metrics to assess therapeutic equivalence of some multiphasic modified-release productsPeter M Kondra, Laszlo Endrenyi, Laszlo Tothfalusi
Statistics in Medicine|August 21, 2012
Comments on the FDA draft guidance on biosimilar productsShein-Chung Chow, Laszlo Endrenyi, Peter A Lachenbruch
Statistics in Medicine|August 23, 2012
On the interchangeability of biologic drug productsLaszlo Endrenyi, Chiann Chang, Shein-Chung Chow, et al.
Statistics in Medicine|August 31, 2012
Scientific considerations for assessing biosimilar productsShein-Chung Chow, Jun Wang, Laszlo Endrenyi, et al.
Journal of Biopharmaceutical Statistics|August 8, 2014
Scientific factors and current issues in biosimilar studiesShein-Chung Chow, Laszlo Endrenyi, Peter A Lachenbruch, et al.
Statistics in Medicine|August 31, 2012
Impact of variability on the choice of biosimilarity limits in assessing follow-on biologicsNan Zhang, Jun Yang, Shein-Chung Chow, et al.
Pharmacogenetics and Genomics|December 14, 2007
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazineEleni Aklillu, Werner Kalow, Laszlo Endrenyi, et al.
Omics : a Journal of Integrative Biology|October 31, 2017
Stop the Spam! Conference Ethics and Decoding the Subtext in Post-Truth Science. What Would Denis Diderot Say?Vural Özdemir, Collet Dandara, Nezih Hekim, et al.
Clinical Therapeutics|April 20, 2012
Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteriaMegan J Shram, Anne Marie Quinn, Nancy Chen, et al.
Journal of Clinical Psychopharmacology|March 2, 2005
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategyLawrence J Albers, Vural Ozdemir, Stephen R Marder, et al.
Pageof 4